A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME

Registry ID

DNLI-E-0002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

DENALI THERAPEUTICS INC.

Start date

2023-04-18

Last update

2021-08-12

Conditions

• HUNTER SYNDROME

Related clinical trials

• AN OPEN-LABEL EXTENSION FOR SUBJECTS IN STUDIES HGT-HIT-046 AND SHP609-302 EVALUATING LONG-TERM SAFETY OF INTRATHECAL IDURSULFASE-IT ADMINISTERED IN CONJUNCTION WITH INTRAVENOUS ELAPRASE® IN SUBJECTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT
• "AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT."
• A CONTROLLED, RANDOMIZED, TWO-ARM, OPEN-LABEL, ASSESSOR-BLINDED, MULTICENTER STUDY OF INTRATHECAL IDURSULFASE-OT ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PEDIATRIC PATIENTS WITH HUNTER SYNDROME AND EARLY COGNITIVE IMPAIRMENT

View on source registry